Trevi Therapeutics (TRVI)

• Market cap: $1.89B
• 1 day: -4.31%
• 5 days: -5.12%
• 1 month: -9.07%
• 3 months: 1.91%
• 6 months: -1.04%
• Year to date: 12.11%
• 1 year: 97.77%
• 5 years: 514.29%
• 10 years: 68.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Employees: 34